Illumina, Inc. (NASDAQ:ILMN - Free Report) - Leerink Partnrs lowered their Q4 2025 EPS estimates for Illumina in a research report issued on Tuesday, January 7th. Leerink Partnrs analyst P. Souda now anticipates that the life sciences company will earn $1.24 per share for the quarter, down from their previous forecast of $1.25. The consensus estimate for Illumina's current full-year earnings is $4.11 per share. Leerink Partnrs also issued estimates for Illumina's FY2026 earnings at $4.90 EPS.
Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter in the prior year, the company earned $0.33 EPS. Illumina's quarterly revenue was down 3.5% on a year-over-year basis.
Other equities research analysts have also issued research reports about the company. Leerink Partners upped their price objective on Illumina from $160.00 to $200.00 and gave the stock an "outperform" rating in a research report on Thursday, October 17th. Hsbc Global Res upgraded Illumina from a "hold" rating to a "strong-buy" rating and set a $180.00 price objective on the stock in a research report on Thursday, October 17th. Piper Sandler lowered their price objective on Illumina from $195.00 to $185.00 and set an "overweight" rating on the stock in a research report on Monday, November 11th. Citigroup lowered Illumina from a "buy" rating to a "neutral" rating and decreased their target price for the company from $190.00 to $165.00 in a research report on Wednesday, December 11th. Finally, Canaccord Genuity Group increased their target price on Illumina from $130.00 to $145.00 and gave the company a "hold" rating in a research report on Tuesday, November 5th. Eight analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $165.95.
Read Our Latest Research Report on ILMN
Illumina Stock Performance
NASDAQ:ILMN traded up $0.60 during midday trading on Wednesday, hitting $139.68. The company's stock had a trading volume of 1,342,769 shares, compared to its average volume of 1,406,074. Illumina has a fifty-two week low of $100.08 and a fifty-two week high of $156.66. The firm's 50 day moving average is $141.46 and its 200-day moving average is $132.03. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The firm has a market cap of $22.15 billion, a P/E ratio of -14.02 and a beta of 1.11.
Institutional Trading of Illumina
Hedge funds and other institutional investors have recently modified their holdings of the business. Zacks Investment Management acquired a new stake in shares of Illumina during the 3rd quarter worth about $2,924,000. Freemont Management S.A. purchased a new position in Illumina during the 3rd quarter valued at about $1,565,000. Weybosset Research & Management LLC boosted its holdings in Illumina by 92.0% during the 3rd quarter. Weybosset Research & Management LLC now owns 18,052 shares of the life sciences company's stock valued at $2,354,000 after acquiring an additional 8,650 shares during the period. B. Riley Wealth Advisors Inc. boosted its holdings in Illumina by 176.3% during the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 7,176 shares of the life sciences company's stock valued at $749,000 after acquiring an additional 4,579 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Illumina by 65.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 32,806 shares of the life sciences company's stock valued at $4,278,000 after acquiring an additional 12,986 shares during the period. 89.42% of the stock is owned by institutional investors and hedge funds.
Illumina Company Profile
(
Get Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Further Reading
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
